FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308402169> ?p ?o ?g. }

• W4308402169 abstract "<h3>Background</h3> Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 CAR T-cell therapy approved for patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) and follicular lymphoma. In the ZUMA-1 pivotal study, Grade ≥3 cytokine release syndrome (CRS) and neurological events (NE) were observed in 13% and 28% of patients, with median time to onset of any grade at 2 and 5 days, respectively.¹ Using conventional low-throughput platforms (eg, multiplex ELISA), pretreatment markers, including serum levels of LDH, IL-6, and IL-15, demonstrated a positive association with Grade ≥3 CRS and/or NE.² We sought to explore biological mechanisms and novel markers underlying the development of early-onset (within 5 days post-CAR T-cell infusion) Grade ≥3 CRS and NE using high-throughput Olink^® proteomic profiling. <h3>Methods</h3> Serum samples collected prior to conditioning chemotherapy (baseline) and immediately prior to CAR T-cell therapy (Day 0) for 142 patients with R/R LBCL treated in ZUMA-1 Phase 2 Cohorts 1, 2, and 4 were analyzed by Olink^® panels comprising 1,458 markers. Association between marker expression and early Grade ≥3 toxicity was evaluated using Wilcoxon test and logistic regression. Weighted gene coexpression network analysis (WGCNA)³ was performed to identify highly coexpressed protein clusters, which were used for gene ontology (GO) analysis for biological interpretation. Machine learning methods were used to select features and build classifiers. <h3>Results</h3> Twenty-four patients (17%) experienced Grade ≥3 CRS and/or NE within 5 days post–CAR T-cell infusion. Univariate and WGCNA analyses demonstrated that clusters of pretreatment markers were associated with these toxicities; these clusters correlated positively with poor prognosis factors (eg, International Prognostic Index and baseline tumor burden). GO analysis applied to these clusters showed enrichment of proteins involved in metabolic processes and leukocyte activation. Machine learning demonstrated excellent performance (mean AUC >0.80 in both training and testing runs) of groups of Olink^® markers in classifying patients with early high-grade toxicity. Further, we observed that IL-1/IL-6 pathway markers (eg, IL-1A and OSMR) were useful in identifying Grade ≥3 CRS, while inflammatory endothelial markers (eg, ACE2, CEACAM1, ICAM2, and ADAM15) could classify patients with both Grade ≥3 CRS and NE upon axi-cel treatment. <h3>Conclusions</h3> Our proteomic analysis supports the relevance of previously described markers. In addition, we have identified potential markers that are mechanistically involved in the development of high-grade toxicity. Safety of CAR T-cell therapy may be improved by optimization of product or conditioning regimen to reduce adverse event-dependent proinflammatory activities while maintaining efficacy. KS and GT contributed equally. <h3>References</h3> Neelapu SS, Locke FL, Bartlett NL, <i>et al</i>. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. <i>N Engl J Med</i>. 2017;<b>377</b>(26):2531–2544. Locke FL, Rossi JM, Neelapu SS, <i>et al</i>. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. <i>Blood Adv</i>. 2020;<b>4</b>(19):4898–4911. Langfelder P, Horvath S. WGNCA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;<b>9</b>:559. <h3>Ethics Approval</h3> The study was approved by the institutional review board at each study site and was conducted in accordance with the Good Clinical Practice guidelines of the International Conference on Harmonization. All the patients provided written informed consent." @default.
• W4308402169 created "2022-11-11" @default.
• W4308402169 creator A5005498754 @default.
• W4308402169 creator A5009635192 @default.
• W4308402169 creator A5021394406 @default.
• W4308402169 creator A5036293139 @default.
• W4308402169 creator A5037526878 @default.
• W4308402169 creator A5037957302 @default.
• W4308402169 creator A5039631748 @default.
• W4308402169 creator A5040504519 @default.
• W4308402169 creator A5050044011 @default.
• W4308402169 creator A5058790135 @default.
• W4308402169 creator A5064185471 @default.
• W4308402169 creator A5069450479 @default.
• W4308402169 creator A5091739351 @default.
• W4308402169 date "2022-11-01" @default.
• W4308402169 modified "2023-09-25" @default.
• W4308402169 title "687 Proteomic profiling in blood identifies novel pretreatment and mechanistic markers related to inflammatory adverse events in relapsed/refractory large B-cell lymphoma after axicabtagene ciloleucel" @default.
• W4308402169 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0687" @default.
• W4308402169 hasPublicationYear "2022" @default.
• W4308402169 type Work @default.
• W4308402169 citedByCount "0" @default.
• W4308402169 crossrefType "proceedings-article" @default.
• W4308402169 hasAuthorship W4308402169A5005498754 @default.
• W4308402169 hasAuthorship W4308402169A5009635192 @default.
• W4308402169 hasAuthorship W4308402169A5021394406 @default.
• W4308402169 hasAuthorship W4308402169A5036293139 @default.
• W4308402169 hasAuthorship W4308402169A5037526878 @default.
• W4308402169 hasAuthorship W4308402169A5037957302 @default.
• W4308402169 hasAuthorship W4308402169A5039631748 @default.
• W4308402169 hasAuthorship W4308402169A5040504519 @default.
• W4308402169 hasAuthorship W4308402169A5050044011 @default.
• W4308402169 hasAuthorship W4308402169A5058790135 @default.
• W4308402169 hasAuthorship W4308402169A5064185471 @default.
• W4308402169 hasAuthorship W4308402169A5069450479 @default.
• W4308402169 hasAuthorship W4308402169A5091739351 @default.
• W4308402169 hasBestOaLocation W43084021691 @default.
• W4308402169 hasConcept C126322002 @default.
• W4308402169 hasConcept C143998085 @default.
• W4308402169 hasConcept C203014093 @default.
• W4308402169 hasConcept C2777058707 @default.
• W4308402169 hasConcept C2777257650 @default.
• W4308402169 hasConcept C2778559949 @default.
• W4308402169 hasConcept C2779338263 @default.
• W4308402169 hasConcept C71924100 @default.
• W4308402169 hasConcept C90924648 @default.
• W4308402169 hasConceptScore W4308402169C126322002 @default.
• W4308402169 hasConceptScore W4308402169C143998085 @default.
• W4308402169 hasConceptScore W4308402169C203014093 @default.
• W4308402169 hasConceptScore W4308402169C2777058707 @default.
• W4308402169 hasConceptScore W4308402169C2777257650 @default.
• W4308402169 hasConceptScore W4308402169C2778559949 @default.
• W4308402169 hasConceptScore W4308402169C2779338263 @default.
• W4308402169 hasConceptScore W4308402169C71924100 @default.
• W4308402169 hasConceptScore W4308402169C90924648 @default.
• W4308402169 hasLocation W43084021691 @default.
• W4308402169 hasOpenAccess W4308402169 @default.
• W4308402169 hasPrimaryLocation W43084021691 @default.
• W4308402169 hasRelatedWork W180184565 @default.
• W4308402169 hasRelatedWork W1978932947 @default.
• W4308402169 hasRelatedWork W2020184844 @default.
• W4308402169 hasRelatedWork W2028697669 @default.
• W4308402169 hasRelatedWork W2139294331 @default.
• W4308402169 hasRelatedWork W2407970965 @default.
• W4308402169 hasRelatedWork W2592912494 @default.
• W4308402169 hasRelatedWork W3032693685 @default.
• W4308402169 hasRelatedWork W3121532487 @default.
• W4308402169 hasRelatedWork W4286203519 @default.
• W4308402169 isParatext "false" @default.
• W4308402169 isRetracted "false" @default.
• W4308402169 workType "article" @default.